Board of Directors

Dr. Martin Faulkes has over 30 years of entrepreneurial and managerial experience as the founder and CEO of several software companies within the United Kingdom and the United States.

From 1979 to 1984, Dr. Faulkes was the Founder, President and CEO for Logica Inc., a company providing bespoke software to all industries but mainly banks and communications companies. Dr. Faulkes was responsible for all aspects of the business; namely sales, finance, recruitment,staff management and project control. He then became Managing Director of System Programming Ltd., a company that provides computer programming for systems in business like airlines, utility companies, banks, and insurance, from 1985 to 1987, where he was responsible for all aspects of the business. Dr. Faulkes founded Triad Plc., a computer software development company that provides systems and consultants to the business community, where he was a director from 1987 to 1998, responsible for controlling the company financially.

From 1998 until the present day, Dr. Faulkes has focused on charitable activities, as the Founder and Sole Benefactor of the Dill Faulkes Educational Trust, a UK registered charity, where he is Chairman. He also sits on the Board of the Cambridge 800th Anniversary Campaign in the UK.

Cameron is an experienced entrepreneurial executive, with expertise in biotechnology companies. He has extensive experience in the management, structuring, and strategic planning of start-up companies and has held positions including Chief Executive Officer, Chief Financial Officer, and Non-Executive Director of public and private enterprises.

Cameron was educated at the University of Western Australia receiving both a Bachelor of Commerce and an MBA.

Alan Colman obtained a BA degree in Biochemistry in Oxford (1971) and a PhD under John Gurdon, a pioneer of the field of nuclear transfer, at the Laboratory of Molecular Biology in Cambridge, UK (1974). After a series of academic appointments in Oxford and Warwick Universities, he became Professor of Biochemistry in the University of Birmingham, UK from 1987-1992. The focus then of his academic career was the area of eucaryotic protein secretion, with a particular emphasis on the use of frog oocytes and eggs as in vivo test tubes.

From 1987 until March 2002, he was research director of the company PPL Therapeutics in Edinburgh, UK. This company specialized in the production of transgenic livestock that produced human therapeutic proteins in their milk.  PPL attracted considerable media attention because of their use of somatic cell nuclear transfer in a collaboration with the neighboring Roslin Institute. This work led to Dolly, the world’s first sheep cloned from an adult somatic cell (1996).

From 2002-2007, he was CSO and then CEO for the Singaporean human embryonic stem cell company, ES Cell International.  Following this, he served as Executive Director of the Singapore Stem Cell Consortium and a Principal Investigator at the Singapore A*STAR Institute of Medical Biology (2006-2013) whilst concurrently Professor of Regenerative Medicine at King’s College, London, UK (2008-2009). His main research interest during these appointments was the development of human disease models using induced pluripotent stem cells.

In addition to his roles with Volition (2011- present ), Dr. Alan Colman acts as senior scientific advisor to Genea Biocells in San Diego, USA, and is a Visiting Scholar at the Harvard University Department of Stem Cell and Regenerative Biology (2014- present).

Guy Archibald Innes is a Chartered Accountant and a member of the Institute of Chartered Accountants in England and Wales.

Mr. Innes has extensive experience in financing and managing technology companies, which he gained from serving as a non-executive director on the board of companies such as ProBio Inc. from 2000 to 2006, Magellan Copper & Gold Plc. from 2007 to 2010, and Carbon Mining Plc. from 2007 to 2010.

Prior to holding these directorships, Mr. Innes had a long career in banking and private equity, including advisory roles with Baring Brothers & Co. Limited in London and Paris from 1984 to 1995, where he was involved in executing and advising on national and international mergers & acquisitions, but also IPOs and capital raising; Baring Private Equity Partners Limited in London and Singapore from 1995 to 1997, where he was involved in the setting up, recruiting of managers and capital raising for an Asian media and communications private equity fund; and Quartz Capital Partners Limited from 1997 to 2000, where Mr. Innes served as Head of Corporate Finance and was responsible for managing the corporate finance department and leading the transactions undertaken by Quartz including IPOs, private placements and mergers and acquisitions.

Mr. Innes was educated at the University of Bristol (BSc Geography), and is a Member of the Institute of Chartered Accountants in England and Wales.

Dr. Futcher holds a B.Sc. in Physics and a Ph.D. in Physics from the University of London and has extensive experience in engineering and management in high technology companies.  Since 1997, Dr. Futcher has held non-executive directorships at a variety of private companies. He co-founded Azima, Inc. in 2003, a company that provides advanced machine diagnosis to large industrial facilities and, from 2003 to 2008, served as its Vice President of Engineering. Prior to that, from 1997 to 2003, Dr. Futcher served as Vice President of Technology at interWAVE Communications International Ltd., a company providing GSM and CDMA cellular infrastructure equipment, and from 1997 to 1999 he also served as interWAVE's Vice President of Engineering.  From 1994 to 1997, Dr. Futcher was Director of Engineering at Tellabs, Inc.

Dr. Habib Skaff is a synthetic chemist specializing in the area of nanotechnology. He currently serves as Managing Partner of Cedar Capital Holdings, LLC, where he heads operations as well as acquisitions of companies in fields from wound care to recycling. Until 2016, Dr. Skaff served as Chief Executive Officer of Intezyne Technologies, which he co-founded in 2004.

Dr. Skaff received a Ph.D. in Polymer Science and Engineering from the University of Massachusetts, Amherst. His doctoral studies involved the design of organic and polymeric ligands for the encapsulation of semiconductor nanoparticles and modification of the physical, optical, electronic, and assembly properties of the nanoparticles. He also earned a M.S. in Polymer Science and Engineering from the University of Massachusetts and a B.S. degree in Materials Science and Engineering (Honors) from the University of Florida. He has co-authored 11 peer-reviewed scientific papers and is a co-inventor on 18 pending or issued patents in the fields of chemistry, nanotechnology, and biotechnology.

arrow-down arrow-left arrow-right arrow chevron-down circle-link--red circle-link close play plus